Showing results (951-960 of 1,211) with videos related to

Sort By:
Pageof 122
American Heart Journal|May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVERAnkeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
European Journal of Heart Failure|May 21, 2023
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HFSafia Chatur, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection FractionSara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
European Heart Journal|August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillationToru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
JACC. Asia|November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFKieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
The New England Journal of Medicine|July 6, 2017
Declining Risk of Sudden Death in Heart FailureLi Shen, Pardeep S Jhund, Mark C Petrie, et al.
Circulation|November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trialMarc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 21, 2025
Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEFMingming Yang, Alasdair D Henderson, Inder S Anand, et al.
Pageof 122